Investment Thesis
CRISPR Therapeutics faces critical operational deterioration with revenue collapsing 90.6% YoY to $1.5M while sustaining -$130.2M operating losses and burning -$109.4M in free cash flow annually. Despite a fortress balance sheet providing estimated 4-5 year runway, the company shows no profitability trajectory and is rapidly consuming shareholder capital with negative margins exceeding -8400%.
Strengths
- Exceptional liquidity position with 17.96x current ratio and $423.3M cash providing multi-year operational runway
- Conservative leverage at 0.32x debt-to-equity with manageable $585.5M long-term debt
- Substantial $2.7B asset base and $1.8B stockholders' equity provides financial flexibility
Risks
- Revenue collapse of 90.6% YoY to $1.5M signals severe loss of revenue stream or major contract termination
- Negative free cash flow of -$109.4M annually with no visible path to cash flow breakeven
- Operating losses of -$130.2M require successful clinical breakthroughs or external financing within finite cash runway
Key Metrics to Watch
- Quarterly revenue stabilization and new partnership/contract announcements
- Operating cash flow recovery trajectory and monthly burn rate trends
- Clinical trial advancement milestones and regulatory approval progress
- Cash balance depletion rate and need for equity or debt financing
Financial Metrics
Revenue
1.5M
Net Income
-122.9M
EPS (Diluted)
$-1.28
Free Cash Flow
-109.4M
Total Assets
2.7B
Cash
423.3M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-8,933.3%
Net Margin
-8,431.5%
ROE
-6.8%
ROA
-4.5%
FCF Margin
-7,503.5%
Balance Sheet & Liquidity
Current Ratio
17.96x
Quick Ratio
17.96x
Debt/Equity
0.32x
Debt/Assets
33.4%
Interest Coverage
-235.53x
Long-term Debt
585.5M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-07T08:31:56.031076 |
Data as of: 2026-03-31 |
Powered by Claude AI